​

Compass Therapeutics (CMPX) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

CMPX Stock Forecast

Compass Therapeutics (CMPX) stock forecast, based on 15 Wall Street analysts, predicts a 12-month average price target of $11.20, with a high of $15.00 and a low of $9.00. This represents a 532.77% increase from the last price of $1.77.

- $3 $6 $9 $12 $15 High: $15 Avg: $11.2 Low: $9 Last Closed Price: $1.77

CMPX Stock Rating

Compass Therapeutics stock's rating consensus is Buy, based on 15 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 15 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 15 0 15 Strong Sell Sell Hold Buy Strong Buy

CMPX Price Target Upside V Benchmarks

TypeNameUpside
StockCompass Therapeutics532.77%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-36
Avg Price Target-$12.33$11.00
Last Closing Price$1.77$1.77$1.77
Upside/Downside-596.61%521.47%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 26313---16
Mar, 26313---16
Feb, 26312---15
Jan, 26311---14
Dec, 2529---11
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 05, 2026Maury RaycroftJefferies$9.00$5.5362.75%408.47%
Feb 13, 2026Craig-Hallum$15.00$6.52130.06%747.46%
Feb 04, 2026Canaccord Genuity$13.00$6.42102.49%634.46%
Jan 06, 2026Sean McCutcheonRaymond James$9.00$4.8984.05%408.47%
Dec 03, 2025Reni BenjaminJMP Securities$10.00$5.2291.57%464.97%
Oct 06, 2025Compass Point$10.00$3.70170.27%464.97%
Apr 02, 2025Andrew BerensLeerink Partners$6.00$1.69255.03%238.98%
Sep 16, 2024Aydin HuseynovCompass Point$5.00$1.65203.03%182.49%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 28, 2026Raymond JamesOutperformMarket Performdowngrade
Apr 27, 2026H.C. WainwrightBuyBuyhold
Mar 12, 2026Cantor FitzgeraldOverweightOverweighthold
Mar 05, 2026JefferiesBuyBuyhold
Mar 05, 2026William BlairOutperformOutperformhold
Mar 05, 2026Raymond JamesOutperformOutperformhold
Feb 13, 2026Craig-HallumBuyinitialise
Jan 06, 2026Raymond JamesOutperformOutperformhold
Jan 05, 2026William BlairOutperforminitialise
Dec 03, 2025Cantor FitzgeraldOverweightinitialise

Financial Forecast

EPS Forecast

$-15 $-6 $3 $12 $21 $30 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.33$-0.36$-0.42---
Avg Forecast$-0.33$-0.35$-0.40$-0.45$-0.03$0.78
High Forecast$-0.31$-0.32$-0.26$0.34$26.30$1.13
Low Forecast$-0.40$-0.40$-0.63$-1.28$-13.50$0.44
Surprise %-2.86%5.00%---

Revenue Forecast

$0 $100M $200M $300M $400M $500M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-$850.00K----
Avg Forecast-$907.14K$6.22M$61.18M$180.20M$364.77M
High Forecast-$927.76K$8.33M$61.18M$184.89M$488.96M
Low Forecast-$876.22K$4.10M$61.18M$175.51M$240.57M
Surprise %--6.30%----

Net Income Forecast

$-2B $-900M $200M $1B $2B $4B Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-42.49M$-49.38M$-66.49M---
Avg Forecast$-42.49M$-47.76M$-61.25M$-65.80M$788.86K$99.59M
High Forecast$-39.72M$-40.65M$-32.88M$42.75M$3.34B$143.67M
Low Forecast$-51.25M$-50.81M$-79.86M$-162.72M$-1.71B$55.51M
Surprise %-3.39%8.56%---

CMPX Forecast FAQ

Is Compass Therapeutics stock a buy?

Compass Therapeutics stock has a consensus rating of Buy, based on 15 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 15 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Compass Therapeutics is a favorable investment for most analysts.

What is Compass Therapeutics's price target?

Compass Therapeutics's price target, set by 15 Wall Street analysts, averages $11.2 over the next 12 months. The price target range spans from $9 at the low end to $15 at the high end, suggesting a potential 532.77% change from the previous closing price of $1.77.

How does Compass Therapeutics stock forecast compare to its benchmarks?

Compass Therapeutics's stock forecast shows a 532.77% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Compass Therapeutics over the past three months?

  • April 2026: 18.75% Strong Buy, 81.25% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2026: 18.75% Strong Buy, 81.25% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Compass Therapeutics’s EPS forecast?

Compass Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.45, marking a 7.14% increase from the reported $-0.42 in 2025. Estimates for the following years are $-0.03 in 2027, and $0.78 in 2028.

What is Compass Therapeutics’s revenue forecast?

Compass Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $61.18M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $180.2M, and $364.77M for 2028.

What is Compass Therapeutics’s net income forecast?

Compass Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-65.804M, representing a -1.03% decrease from the reported $-66.489M in 2025. Projections indicate $788.86K in 2027, and $99.59M in 2028.